• 1
    Janossy G, Panayi GS, Duke O, Bofill M, Poulter LW, Goldstein G. Rheumatoid arthritis. a disease of T-lymphocyte/macrophage immunoregulation. Lancet 1981; 2: 83942.
  • 2
    Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 90716.
  • 3
    Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid arthritis. Arthritis Rheum 1990; 33: 76874.
  • 4
    Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35: 72934.
  • 5
    Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997; 40: 598609.
  • 6
    Miossec P. Are T cells in rheumatoid synovium aggressors or bystanders? Curr Opin Rheumatol 2000; 12: 1815.
  • 7
    Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 2636.
  • 8
    Miossec P, Van Den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40: 210515.
  • 9
    Van Roon JAG, Lafeber FPJG, Bijlsma JWJ. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001; 44: 312.
  • 10
    Weiner HL, Inobe J, Kuhroo V, Chen Y. Induction and characterization of TGF β secreting cells [abstract]. FASEB J 1996; 10A: A1444.
  • 11
    Sher A, Coffman RL. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol 1992; 10: 385409.
  • 12
    Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 73742.
  • 13
    Yudoh K, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum 2000; 43: 61727.
  • 14
    Miltenburg AM, Van Laar JM, De Kuiper R, Daha MR, Breedveld FC. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol 1992; 35: 60310.
  • 15
    Quayle AJ, Choromat P, Miossec P, Kjeldsen-Kragh J, Forre O, Natvig JB. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand J Immunol 1993; 38: 7582.
  • 16
    Dolhain RJEM, Van der Heiden AN, Ter Haar NT, Breedveld FC, Miltenburg AMM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 9: 19619.
  • 17
    Nanki T, Lipsky PE. Cytokine, activation marker, and chemokine recptor expression by individual CD4+ memory T cells in rheumatoid arthritis synovium. Arthritis Res 2000; 2: 41523.
  • 18
    Rep MH, Van Oosten BW, Roos MT, Ader HJ, Polman CH, Van Lier RA. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-γ secreting Th1 cells in humans. J Clin Invest 1997; 99: 222531.
  • 19
    Van Roon JA, Verhoef CM, Nan Roy JL et al. Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis 1997; 56: 65660.
  • 20
    Maurice MM, Van Der Graaf WL, Leow A, Breedveld FC, Van Lier RAW, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 216673.
  • 21
    Doncarli A, Stasiuk LM, Fournier C, Abehsira-Amar O. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur J Immunol 1997; 27: 14518.
  • 22
    Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001; 22: 727.
  • 23
    Fox DA, Millard JA, Kan L et al. Activation pathways of synovial T lymphocytes: expression and function of the UM4D4/CDw60 antigen. J Clin Invest 1990; 86: 112436.
  • 24
    Cooper SM, Dier DL, Roessner KD, Budd RC, Nicklas JA. Diversity of rheumatoid synovial tissue T cells by T cell receptor analysis: oligoclonal expansion in interleukin-2-responsive cells. Arthritis Rheum 1991; 34: 53746.
  • 25
    Cohen SBA, Katsikis PD, Chu C-G et al. High IL-10 production by the activated T cell population in the rheumatoid synovial membrane. Arthritis Rheum 1995; 38: 94652.
  • 26
    Cohen SBA, Webb LMC, Feldmann M. The method of deriving human T-cell clones alters the proportion of IL-10-producing cells. Immunology 1996; 87: 3436.
  • 27
    Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 28
    Londei M, Gruback-Loebenstein B, De Berardinis P, Greenall C, Feldmann M. Efficient propagation and cloning of human T cells in the absence of antigen by means of OKT3, interleukin-2 and antigen presenting cells. Scand J Immunol 1988; 27: 3541.
  • 29
    Aarvak T, Chabaud M, Kallberg E, Miossec P, Natvig JB. Change in the Th1/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium. Scand J Immunol 1999; 50: 19.DOI: 10.1046/j.1365-3083.1999.00581.x
  • 30
    Ferrini S, Bottino C, Biassoni R et al. Characterization of CD3+, CD4-, CD8- clones expressing the putative T cell receptor γ gene product. J Exp Med 1987; 166: 27782.
  • 31
    Moingeon P, Jitsukawa S, Faure F et al. A γ-chain complex forms a functional receptor on cloned human lymphocytes with natural killer-like activity. Nature 1987; 325: 7236.
  • 32
    Dianzani U, Zarcone D, Pistoia V et al. CD8+ CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. Eur J Immunol 1989; 19: 103744.
  • 33
    Gattorno M, Facchetti P. Ghiotto et al. Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0-type pattern of cytokine secretion irrespective of immunophenotype. Clin Exp Immunol 1997; 109: 411.
  • 34
    Gerli R, Pitzalis C, Bistoni O et al. CD30+ T cells in rheumatoid synovitis. mechanisms of recruitment and functional role. J Immunol 2000; 164: 4399407.
  • 35
    Gerli R, Bertotto A, Rambotti P, Barbieri P, Ciompi ML, Bombardieri S. T cell immunoregulation in rheumatoid synovitis. Arthritis Rheum 1988; 31: 10756.
  • 36
    Cush JJ, Pietshmann P, Oppenheimer-Marks N, Lipsky PE. The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. Arthritis Rheum 1992; 35: 143440.
  • 37
    Adams DH, Shaw S. Leukocyte–endothelial interactions and regulation of leukocyte migration. Lancet 1994; 343: 8315.
  • 38
    Hamann A, Syrbe U. T-cell trafficking into sites of inflammation. Rheumatology 2000; 39: 6969.DOI: 10.1093/rheumatology/39.7.696
  • 39
    Van der Graaf WL, Prins APA, Niers TMH, Dijkmans BAC, Van Lier RAW. Quantitation of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology 1999; 38: 21420.DOI: 10.1093/rheumatology/38.3.214
  • 40
    Berner B, Akça D, Jung T, Muller GA, Reuss-Borst MA. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000; 27: 112835.
  • 41
    Schumacher HR, Kitridou RC. Synovitis of recent onset: a clinico-pathologic study during the first month of disease. Arthritis Rheum 1972; 15: 46585.
  • 42
    Konttinen YT, Bergroth V, Nordström D et al. Cellular immunohistology of acute, subacute, and chronic synovitis in rheumatoid arthritis. Ann Rheum Dis 1985; 44: 54955.
  • 43
    Tak PP, Smeets TJM, Daha MR et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40: 21725.
  • 44
    VanderBorght A, Geusens P, Vandevyver C, Raus J, Stinissen P. Skewed T-cell receptor variable gene usage in the synovium of early and chronic rheumatoid arthritis patients and persistence of clonally expanded T cell in a chronic patient. Rheumatology 2000; 39: 1189201.DOI: 10.1093/rheumatology/39.11.1189
  • 45
    Rudwaleit M, Yin Z, Siegert S et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumor necrosis factor α, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Di 2000; 59: 3114.
  • 46
    Konttinen YT, Nordström D, Santavirta S, Bergroth V. Is one year early, or too late? Comment on the article by Tak. Arthritis Rheum 1997; 40: 19123.
  • 47
    Boers M, Van Verhoeven AC, Markusse HM et al. Randomised comparison of combined prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.
  • 48
    Breitfeld D, Ohl L, Kremmer E et al. Follicular B helper T cells express CXC chemochine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 4: 154552.
  • 49
    Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemochine receptor 5 expression defines follicular homing T cells with B cells helper function. J Exp Med 2000; 4: 155362.
  • 50
    Howard MA, O'Garra H, Ishida H, De Waal Malefyt R, De Vries JE. Biological properties of interleukin 10. J Clin Immunol 1992; 12: 23947.
  • 51
    De Waal Malefyt Yssel H, Roncarolo MG, Spits H, De Vries JE. Interleukin 10. Curr Opin Immunol 1992; 4: 31420.
  • 52
    Isomäki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996; 39: 38695.
  • 53
    Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Interleukin-10 expression and chemochine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995; 95: 286879.
  • 54
    Cush JJ, Splawski JB, Thomas R et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 96104.
  • 55
    Arend WP. The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997; 40: 5957.
  • 56
    Constantin A, Loubet-Lescoulie P, Lambert N et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998; 41: 4857.
  • 57
    Gerli R, Bistoni O, Lunardi C et al. Soluble CD30 in early rheumatoid arthritis as predictor of good response to second line therapy. Rheumatology 1999; 38: 12826.
  • 58
    Joosten LAB, Lubberts E, Durez P et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 24960.
  • 59
    Van Roon JAG, Gmelig-Mevling FHJ, Lafeber FPJG, Bijlsma JWJ. In vitro additive suppression of antigen-induced inflammation in rheumatoid arthritis by IL-10 and IL-4. Arthritis Rheum (Abstract) 1997; 40: (9S):S39
  • 60
    Roncarolo MG, Levings MK. The role of different subsets of regulatory cells in controlling autoimmunity. Curr Opin Immunol 2000; 12: 67683.
  • 61
    Suto A, Nakajima H, Ikeda K et al. CD4+CD25+ T-cell development is regulated by at least 2 distinct mechanisms. Blood 2002; 99: 555 60.
  • 62
    Huizinga TWJ, Keijsers V, Yanni G et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology 2000; 39: 11808.DOI: 10.1093/rheumatology/39.11.1180